Solid-phase synthesis of 3,5-disubstituted 2,3-dihydro-1,5- benzothiazepin-4(5H)-ones

Journal of Organic Chemistry

Volumn 64, Issue 7, 1999, Pages 2219-2231

  Schwarz, Matthias K ^a,b   Tumelty, David ^a   Gallop, Mark A ^a  

^a AFFYMAX RESEARCH INSTITUTE   (United States)

^b SERONO PHARMACEUTICAL RES INSTITUTE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

1,5 BENZOTHIAZEPINE 4 ONE; BENZOTHIAZEPINE DERIVATIVE; UNCLASSIFIED DRUG;

ALKYLATION; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CYCLIZATION; DRUG SYNTHESIS; POLYMERIZATION; PROTON NUCLEAR MAGNETIC RESONANCE; SOLID PHASE EXTRACTION;

EID: 0033515461     PISSN: 00223263     EISSN: None     Source Type: Journal    
DOI: 10.1021/jo981567p     Document Type: Article

References (49)

1. (a) Rampe, D.; Triggle, D. J. Prog. Drug Res. 1993, 40, 191.
2. (b) Chaffman, M.; Brogden, R. N. Drugs 1985, 29, 387.
3. (a) Pitt, B. Clin. Ther. 1997, 19 (Suppl. A), 3.
4. (b) Ferrari, R. Eur. Heart J. 1997, 18 (Suppl. A), A56.
5. See for example: (a) Slade, J.; Stanton, J. L.; Ben-David, D.; Mazzenga, G. C. J. Med. Chem. 1985, 28, 1517.
6. (b) Wyvratt, M.; Devita, R.; Bochis, R.; Schoen, W. U.S. Patent 5,672,596, 1997.
7. (c) Nagel, A. A. PCT Int. Appl. WO 9401421, 1994.
8. For a recent review, see: Lévai, A. Trends Heterocycl. Chem. 1995, 4, 51. See also: Wünsch, K.-H.; Ehlers, A. Z. Chem. 1970, 10, 361
9. For a recent review, see: Lévai, A. Trends Heterocycl. Chem. 1995, 4, 51. See also: Wünsch, K.-H.; Ehlers, A. Z. Chem. 1970, 10, 361
10. (a) Floyd, D. M.; Moquin, R. V.; Atwal, S. K.; Ahmed, S. Z.; Spergel, S. H.; Gougoutas, J. Z.; Malley, M. F. J. Org. Chem. 1980, 55, 5572.
11. (b) Lévai, A.; Puzicha, G. Synth. Commun. 1985, 15, 623.
12. (c) Mayer, F.; Horst, C. Ber. Dtsch. Chem. Ges. 1923, 56, 1415.
13. See for example: (a) Ambrogi, V.; Giampietri, A.; Grandolini, G.; Perioli, L.; Ricci, M.; Tuttobello, L. Arch. Pharm. 1992, 325, 569.
14. (b) Lévai, A.; Duddeck, H. Pharmazie 1983, 38, 827.
15. (c) Krapcho, J.; Spitzmiller, E. R.; Turk, C. F. J. Med. Chem. 1963, 6, 544.
16. (d) Mills, W. H.; Whitworth, J. B. J. Chem. Soc. 1927, 2738.
17. Ambrogi, V.; Grandolini, G. Synthesis 1987, 724.
18. Ried, W.; Sell, G. Chem. Ber. 1980, 113, 2314.
19. See for example: (a) Schwartz, A.; Madan, P. B.; Mohacsi, E.; O'Brien, J. P.; Todaro, L. J.; Coffen, D. L. J. Org. Chem. 1992, 57, 851.
20. (b) Hashiyama, T.; Inoue, H.; Takeda, M.; Murata, S.; Nagao, T. Chem. Pharm. Bull. 1985, 33, 2348.
21. (c) Kugita, H.; Inoue, H.; Ikezaki, M.; Konda, M.; Takeo, S. Chem. Pharm. Bull. 1971, 19, 595.
22. See for example: (a) Kaye, P. T.; Mphahlele, M. J. Synth. Commun. 1996, 25, 1495.
23. (b) Lévai, A. Acta Chim. Acad. Sci. Hung. 1981, 107, 361.
24. Schwarz, M. K.; Tumelty, D.; Gallop, M. A. Tetrahedron Lett. 1998, 39, 8397. A synopsis of all results obtained was presented at the 2nd Canadian Conference of Combinatorial Chemistry, Montreal, Canada, Oct. 6 and 7, 1997. Described were solid-phase syntheses of 1,5-benzothiazepin-4-ones, 1,6-benzothiazocin-5-ones, 1,5-benzodiazepin-2-ones, 4-alkoxy-1,4-thiazin-3-ones, quinoxalin-2-ones, and of a thieno-thiazepine.
25. Loading: 0.33 mmol/g.
26. Yan, B.; Kumaravel, G. Tetrahedron 1996, 52, 843.
27. See for example: (a) ref 11.
28. (b) Wei, G. P.; Phillips, G. B. Tetrahedron Lett. 1998, 39, 179.
29. (c) Lee, J.; Murray, W. V.; Rivero, R. A. J. Org. Chem. 1997, 62, 3874.
30. 2 (see Experimental Section).
31. 2) to liberate the products for the purpose of analysis. After thorough evaporation of the solvent and gravimetric estimation of the crude yields, the residues were routinely analyzed by HPLC (UV detection at 220/280 nm) and ESI-MS.
32. Pinori, M.; Di Gregorio, G.; Mascagni, P. In Innovation and Perspectives in Solid-Phase Synthesis; Epton, R., Ed.; Mayflower Worldwide: Kingswinford, 1994; pp 635-638.
33. Abdel-Magid, A. F.; Carson, K. G.; Harris, B. D.; Maryanoff, C. A.; Shah, R. D. J. Org. Chem. 1996, 61, 3849.
34. (a) Szardenings, A. K.; Burkoth, T. S.; Look, G. C.; Campbell D. A. J. Org. Chem. 1996, 61, 6720.
35. (b) Look, G. C.; Murphy, M. M. Campbell, D. A.; Gallop, M. A. Tetrahedron Lett. 1995, 36, 2937.
36. (a) Crotchet, R. A.; Blanton, C. D. Synthesis 1974, 55.
37. (b) Perrault, W. R.; Shephard, K. P.; Lapean, L. A.; Krook, M. A.; Dobrowolski, P. J.; Lyster, M. A.; McMillan, M. W.; Knoechel, D. J.; Evenson, G. N.; Watt, W.; Pearlman, B. A. Org. Process Res. Dev. 1997, 1, 106.
38. 3 see: (c) Zupet, R.; Tisler, M.; Golic, L. J. Heterocycl. Chem. 1991, 28, 1731.
39. (d) Wentrup, C.; Briehl, H.; Lorencak, P.; Vogelbacher, U. J.; Winter, H.-W.; Maquestiau, A.; Flammang, R. J. Am. Chem. Soc. 1988, 110, 1337.
40. Borch, R. F.; Bernstein, M. D.; Durst, H. D. J. Am. Chem. Soc. 1971, 93, 2897.
41. (a) Katritzky, A. R.; Lan, X.; Fan, W.-Q. Synthesis 1994, 445.
42. (b) Katritzky, A. R.; Rachwal, S.; Hitchings, G. J. Tetrahedron 1991, 47, 2683.
43. Kiso, Y.; Yajima, H. Amide-Formation, Deprotection, and Disulfide Formation in Peptide Synthesis. In Peptides: Synthesis, Structures, and Applications; Gutte, B., Ed.; Academic Press: San Diego, New York, Boston, London, Sydney, Tokyo, Toronto, 1995; pp 40-93.
44. The importance of solvent choice with regard to limiting the extent of N-acylureas formation has long been appreciated: Sheehan, J. C.; Goodman, M.; Hess, G. P. J. Am. Chem. Soc. 1958, 78, 1367.
45. See Experimental Section.
46. Terminology based on the absolute configuration at C(3). Compound 38c was not synthesized.
47. (a) Ni, Z.-J.; Maclean, D.; Holmes, C. P:, Murphy, M. M.; Ruhland, B.; Jacobs, J. W.; Gordon, E. M.; Gallop, M. A. J. Med. Chem. 1996, 39, 1601.
48. (b) Maclean, D.; Schullek, J. R.; Murphy, M. M.; Ni, Z.-J.; Gordon, E. M.; Gallop, M. A. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 2805.
49. 2 (loading: 0.41 mmol/g) was differentiated using a 9:1 molar ratio of Fmoc-Cl and Alloc-Cl and, following Fmoc deprotection, coupled with the Rink-type, acid-labile linker p-[(R,S)-[1-(9H-fluoren-9-yl)-methoxyformamido]-2,4-dimethoxybenzyl]- phenoxyacetic acid (Bernatowicz, M. S.; Daniels, S. B.; Köster, H. Tetrahedron Lett. 1989, 30, 4645). Fmoc removal from the latter furnished the starting resin 42.